Mechanism study on regulation of glioblastoma cell proliferation and apoptosis by sciadopitysin combined with CX-4945 through Notch1 pathway

doi:10.3760/cma.j.cn371439-20220118-00061

Abstract

Abstract: ObjectiveTo investigate the effects and mechanism of sciadopitysin combined with CK2 inhibitor CX-4945 on proliferation and apoptosis of glioblastoma U87 cells. Methods Glioblastoma U87 cells were cultured in vitro, and treated with 0.01, 0.10, 1.00, 10.00, 100.00 μmol/L of sciadopitysin respectively. U87 cells were treated with 1.25, 2.50, 5.00, 10.00, 20.00 μmol/L of CX-4945. U87 cells were divided into control group （without any treatment）, sciadopitysin group （100.00 μmol/L of sciadopitysin）, CX-4945 group （5.00 μmol/L of CX-4945）, sciadopitysin combined with CX-4945 group （100.00 μmol/L of sciadopitysin plus 5.00 μmol/L of CX-4945）. MTT method was used to detect cell viability, Caspase3/7 activity assay and Annexin Ⅴ/ PI double staining were used to detect cell apoptosis, and Western blotting was used to detect the expressions of Notch1 pathway related proteins ICN1, HES1 and DLL3. Results The cell viabilities of U87 cells treated with 0, 0.01, 0.10, 1.00, 10.00, 100.00 μmol/L of sciadopitysin were （100.00±6.30）%, （112.02±7.63）%, （140.84±6.73）%, （113.92±7.92）%, （102.60±7.12）% and （73.16±2.74）% respectively, and there was a statistically significant difference （F=55.21, P<0.001）. There were statistically significant differences in the cell viabilities of U87 cells between 0 μmol/L and 0.01, 0.10, 1.00, 100.00 μmol/L of sciadopitysin treatment （P=0.009; P<0.001; P=0.003; P<0.001）. The cell viability of U87 cells was inhibited by 100.00 μmol/L of sciadopitysin, while sciadopitysin at other low concentrations manifested as enhancement or no obvious effect. The cell viabilities of U87 cells treated with 0, 1.25, 2.50, 5.00, 10.00, 20.00 μmol/L of CX-4945 were （100.00±5.53）%, （108.70±10.24）%, （93.14±2.82）%, （81.46±4.92）%, （56.92±3.99）% and （31.24±2.67）% respectively, and there was a statistically significant difference （F=135.18, P<0.001）. There were statistically significant differences in the cell viabilities of U87 cells between 0 μmol/L and 1.25, 5.00, 10.00, 20.00 μmol/L of CX-4945 treatment （P=0.022; P<0.001; P<0.001; P<0.001）. Low concentration （1.25 μmol/L） of CX-4945 enhanced the cell viability of U87 cells, however higher concentrations （5.00, 10.00, 20.00 μmol/L） of CX-4945 shown inhibitory effect. The cell viabilities of U87 cells in the control group, sciadopitysin group, CX-4945 group and sciadopitysin combined with CX-4945 group were （100.00±5.53）%, （71.96±2.10）%, （77.66±4.12）% and （42.56±4.22）% respectively, and there was a statistically significant difference （F=160.56, P<0.001）. There were statistically significant differences between the control group and each treatment groups （all P<0.001）. There were statistically significant differences between the sciadopitysin combined with CX-4945 group and sciadopitysin group, CX-4945 group （both P<0.001）. The Caspase3/7 activities of U87 cells in the above four groups were 2.34±0.47, 4.02±0.22, 3.67±0.32 and 5.85±0.28 respectively, and there was a statistically significant difference （F=55.80, P<0.001）. The apoptosis rates of each groups were （0.40±0.10）%, （17.37±0.57）%, （3.00±0.66）% and （33.47±0.87）% respectively, and there was a statistically significant difference （F=1 822.18, P<0.001）. Further pairwise comparison showed that there were statistically significant differences in Caspase3/7 activities and apoptosis rates between the control group and each treatment groups （P<0.001, P=0.001, P<0.001; P<0.001, P=0.001, P<0.001）. There were statistically significant differences in Caspase3/7 activities and apoptosis rates between the sciadopitysin combined with CX-4945 group and sciadopitysin group, CX-4945 group （all P<0.001）. The protein expression levels of Notch 1 pathway related proteins ICN1 （0.55±0.07 vs. 1.01±0.09）, HES1 （0.66±0.08 vs. 1.00±0.06） and DLL3 （0.74±0.04 vs. 1.01±0.09） in U87 cells decreased significantly after treatment with 100.00 μmol/L of sciadopitysin （t=5.94, P=0.004; t=5.15, P=0.007; t=4.00, P=0.016）. Conclusion Sciadopitysin can synergize with CK2 inhibitor CX-4945 to inhibit the proliferation and promote apoptosis of glioblastoma U87 cells by inhibiting Notch1 signaling pathway.

Key words: Glioblastoma, Cell proliferation, Apoptosis, Receptor, Notch1, Sciadopitysin, CX-4945

Lian Haiwei, Yang Shuorui, Liu Renzhong. Mechanism study on regulation of glioblastoma cell proliferation and apoptosis by sciadopitysin combined with CX-4945 through Notch1 pathway[J]. Journal of International Oncology, 2022, 49(6): 321-326.

Figures/Tables 3

References 13

[1]	Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial[J]. JAMA, 2017, 318(23): 2306-2316. DOI: 10.1001/jama.2017.18718. doi: 10.1001/jama.2017.18718
[2]	Lian H, Su M, Zhu Y, et al. Protein kinase CK2, a potential therapeutic target in carcinoma management[J]. Asian Pac J Cancer Prev, 2019, 20(1): 23-32. DOI: 10.31557/APJCP.2019.20.1.23. doi: 10.31557/APJCP.2019.20.1.23
[3]	Hong H, Benveniste EN. The immune regulatory role of protein kinase CK2 and its implications for treatment of cancer[J]. Biomedicines, 2021, 9(12): 1932. DOI: 10.3390/biomedicines 9121932. doi: 10.3390/biomedicines 9121932
[4]	Zheng Y, McFarland BC, Drygin D, et al. Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma[J]. Clin Cancer Res, 2013, 19(23): 6484-6494. DOI: 10.1158/1078-0432.CCR-13-0265. doi: 10.1158/1078-0432.CCR-13-0265 pmid: 24036851
[5]	D'Amore C, Borgo C, Sarno S, et al. Role of CK 2 inhibitor CX-4945 in anti-cancer combination therapy-potential clinical relevance[J]. Cell Oncol (Dordr), 2020, 43(6): 1003-1016. DOI: 10.1007/s13402-020-00566-w. doi: 10.1007/s13402-020-00566-w
[6]	李艳楠, 左文博, 薛慧, 等. 金松双黄酮的生物活性研究进展[J]. 农产品加工, 2020(23): 82-84. DOI: 10.16693/j.cnki.1671-9646(X).2020.12.023. doi: 10.16693/j.cnki.1671-9646(X).2020.12.023
[7]	赵学梅, 张宏莲, 孔寰宇, 等. 金松双黄酮联用紫杉醇对A549细胞凋亡的影响[J]. 中国临床药理学杂志, 2015, 31(19): 1949-1951. DOI: 10.13699/j.cnki.1001-6821.2015.19.019. doi: 10.13699/j.cnki.1001-6821.2015.19.019
[8]	戴体俊. 合并用药的定量分析[J]. 中国药理学通报, 1998, (5): 479-480.
[9]	Mahmoud BS, AlAmri AH, McConville C. Polymeric nanoparticles for the treatment of malignant gliomas[J]. Cancers (Basel), 2020, 12(1): 175. DOI: 10.3390/cancers12010175. doi: 10.3390/cancers12010175
[10]	Castello J, Ragnauth A, Friedman E, et al. CK2—An emerging target for neurological and psychiatric disorders[J]. Pharmaceuticals (Basel), 2017, 10(1): 7. DOI: 10.3390/ph10010007. doi: 10.3390/ph10010007
[11]	Lian H, Li D, Zhou Y, et al. CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells[J]. Haematologica, 2017, 102(1): e17-e21. DOI: 10.3324/haematol.2016.154013. doi: 10.3324/haematol.2016.154013
[12]	Ji H, Lu Z. The role of protein kinase CK2 in glioblastoma development[J]. Clin Cancer Res, 2013, 19(23): 6335-6337. DOI: 10.1158/1078-0432.CCR-13-2478. doi: 10.1158/1078-0432.CCR-13-2478
[13]	Zhang S, Long H, Yang YL, et al. Inhibition of CK2α down-regulates Notch1 signalling in lung cancer cells[J]. J Cell Mol Med, 2013, 17(7): 854-862. DOI: 10.1111/jcmm.12068. doi: 10.1111/jcmm.12068

[1]	Ren Lu, Xie Xiaoli, Zhang Kun, Wang Lijuan. Effects and mechanisms of dihydroartemisinin combined with carfilzomib on the activity， proliferation， and apoptosis of multiple myeloma cells [J]. Journal of International Oncology, 2024, 51(3): 129-136.
[2]	Zhang Keping, Zhao Yongsheng, Yang Juan, Fu Maoyong. Chlorogenic acid induces mitochondrial dysfunction in lung cancer A549 cells by inhibiting the PI3K-Akt pathway [J]. Journal of International Oncology, 2024, 51(1): 21-28.
[3]	Xiang Yuling, Tan Jiajie, Xiong Yuanguo, Zhao Lirong, Li Chen, Zhang Hong. Effects of Anhydroicaritin on the proliferation， migration and apoptosis of hepatocellular carcinoma cells [J]. Journal of International Oncology, 2023, 50(9): 513-519.
[4]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456.
[5]	Wu Jiali, Zhang Jiahui, Zhang Ping, Xiao Xinyue, Li Rui, Zhang Hongyu. Mechanism of Bcl-2 BH4 selective inhibitor BDA-366 on NK/T cell lymphoma cells [J]. Journal of International Oncology, 2023, 50(7): 413-418.
[6]	Yang Ya, Wang Huili, Liu Yan, Guo Jinfeng, Wang Chunxia, Lyu Min, Shan Changping. Effects of GCSH gene on proliferation and apoptosis of gastric cancer SNU-1 cells [J]. Journal of International Oncology, 2023, 50(5): 257-262.
[7]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin. lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway [J]. Journal of International Oncology, 2023, 50(4): 202-207.
[8]	Zhu Yi, Chen Jian. Mechanism of hydrogen sulfide in tumorigenesis and development and its donor-mediated anti-tumor effects [J]. Journal of International Oncology, 2023, 50(12): 729-733.
[9]	Yang Ya, Ning Xiaofei, Li Bingliang, Yao Hui, Shan Changping, Lyu Min. Study on the mechanism of procyanidin mediated anti gastric cancer SNU-1 cell line by inducing the production of reactive oxygen species [J]. Journal of International Oncology, 2022, 49(5): 257-262.
[10]	Zhou Renbang, Zhang Zhongchuan, Xu Zhiyuan, Zhu Xunbing. MiR-219a-5p inhibits the proliferation, invasion and migration of osteosarcoma U2OS cells by negatively regulating HMGA2 [J]. Journal of International Oncology, 2022, 49(4): 193-198.
[11]	Laibijiang Wusiman, Cao Bowei, Zhang Wenbin, Gao Hua. Effects of exogenous AGR2 on the proliferation and invasion abilities of colon cancer cells [J]. Journal of International Oncology, 2022, 49(2): 73-78.
[12]	Zhang Yongli, Zhang Ruojia, Fan Huancai, Ge Luna, Wang Lin. TXNDC5-Prx2 axis regulates drug resistance of prostate cancer cells [J]. Journal of International Oncology, 2021, 48(8): 473-478.
[13]	Jiang Mengting, Wang Jiachun, Zong Jing. Effects of NFAT5 inhibition on proliferation, invasion, migration and apoptosis of lung adenocarcinoma cells [J]. Journal of International Oncology, 2021, 48(6): 321-327.
[14]	Yan Xingyu, Lian Zhenying, Diao Yutao, Liu Hongyan. BMXΔN mediates gefitinib resistance of lung cancer cells through ERK/MAPK signaling pathway [J]. Journal of International Oncology, 2021, 48(6): 328-334.
[15]	Wang Xianwei, Shi Meiyan, Wang Fengqin, Qi Fu, Wang Chaozhe, Zhou Fei. Roles of TSA upregulation miR-4298 targeting inhibition of PADI4 expression in inducing U251 cells apoptosis [J]. Journal of International Oncology, 2021, 48(4): 193-199.